
---
title: '癌症免疫疗法PI3Kδ抑制剂治疗的不良事件机制'
categories: 
 - 新媒体
 - 科学网
 - 博客
headimg: 'https://cors.zfour.workers.dev/?http://image.sciencenet.cn/home/202205/07/100928qis3l51gq5305fts.png'
author: 科学网
comments: false
date: Sat, 07 May 2022 10:08:00 GMT
thumbnail: 'https://cors.zfour.workers.dev/?http://image.sciencenet.cn/home/202205/07/100928qis3l51gq5305fts.png'
---

<div>   
<p style="margin-left: 0px; line-height: 150%; text-indent: 2em;"><span style=";font-family:仿宋;line-height:150%;font-size:16px"></span></p><p style="line-height: 150%; text-indent: 2em;"><span style=";font-family:宋体;line-height:150%;font-size:19px">癌症免疫疗法药物</span><span style=";font-family:Calibri;line-height:150%;font-size:19px">PI3Kδ</span><span style=";font-family:宋体;line-height:150%;font-size:19px">抑制剂治疗的不良事件机制</span></p><p style="line-height: 150%; text-indent: 2em;"><span style=";font-family:宋体;line-height:150%;font-size:19px"><span style="font-family:宋体">这是最新《自然》杂志的一篇研究论文。该研究利用动物实验，证明目前一种临床免疫治疗药物为什么会导致结肠炎这种不良效应。发现药物能导致结肠组织内</span><span style="font-family:Calibri">Treg</span><span style="font-family:宋体">细胞被剔除，而</span><span style="font-family:Calibri">Th17</span><span style="font-family:宋体">细胞增加。前者是免疫抑制细胞，后者是炎症驱动细胞，因此能导致结肠炎。</span></span></p><p style="line-height: 150%; text-indent: 2em;"><span style=";font-family:宋体;line-height:150%;font-size:19px"><span style="font-family:宋体">这可能给从事结肠炎研究的同行们提供了一种新结肠炎动物模型。据我所知，临床上结肠炎是一种自身免疫性疾病，</span><span style="font-family:Calibri">Treg</span><span style="font-family:宋体">细胞和</span><span style="font-family:Calibri">Th17</span><span style="font-family:宋体">细胞也是最重要的参与细胞类型。过去经常是采用大量口服</span><span style="font-family:Calibri">DSS</span><span style="font-family:宋体">的方法，学术界进行了大量研究。但是</span><span style="font-family:Calibri">DSS</span><span style="font-family:宋体">模型导致结肠炎的机制并不十分清楚。 目前的研究主要认为</span><span style="font-family:Calibri">DSS</span><span style="font-family:宋体">增加肠道通透性、破坏肠黏膜屏障、上调某些细胞因子（肿瘤坏死因子、白介素、干扰素、</span><span style="font-family:Calibri">IL-10</span><span style="font-family:宋体">和</span><span style="font-family:Calibri">IL-12</span><span style="font-family:宋体">）、激活某些通路（</span><span style="font-family:Calibri">NF-</span><span style="font-family:宋体">κ</span><span style="font-family:Calibri">B</span><span style="font-family:宋体">通路和</span><span style="font-family:Calibri">TRPV1</span><span style="font-family:宋体">通路）或肠道菌群失调等有关。如果这样，应该对这两种模型进行对不研究，结合临床结肠炎的特点，对比两种模型那种更接近于人类结肠炎。就我的个人判断，如果免疫模型造模重复性强。这种模式应该更接近人类的疾病。而且进行这方面研究，不仅对于结肠炎本身，而且对这种免疫治疗不良作用也有价值。</span></span></p><p style="line-height: 150%; text-indent: 2em;"><span style=";font-family:Calibri;line-height:150%;font-size:19px">Phosphoinositide 3-kinase δ (PI3Kδ)<span style="font-family:宋体">在淋巴细胞中具有关键作用，靶向</span><span style="font-family:Calibri">PI3K</span><span style="font-family:宋体">的抑制剂已被批准用于治疗</span><span style="font-family:Calibri">B</span><span style="font-family:宋体">细胞恶性肿瘤。虽然实体肿瘤小鼠模型的研究已经证明</span><span style="font-family:Calibri">PI3Kδ</span><span style="font-family:宋体">抑制剂</span><span style="font-family:Calibri">(PI3Kδi)</span><span style="font-family:宋体">可以诱导抗肿瘤免疫，但其对人类实体肿瘤的作用仍不清楚。</span></span><span style=";font-family:Calibri;line-height:150%;font-size:19px"><span style="font-family:宋体">在一项新辅助、双盲、安慰剂对照的随机</span>II<span style="font-family:宋体">期临床试验中，我们评估了</span><span style="font-family:Calibri">PI3Kδi</span></span><span style=";font-family:宋体;line-height:150%;font-size:19px">（</span><span style=";font-family:Calibri;line-height:150%;font-size:19px">AMG319</span><span style=";font-family:宋体;line-height:150%;font-size:19px">）</span><span style=";font-family:Calibri;line-height:150%;font-size:19px"><span style="font-family:宋体">在人类头颈部癌症患者中的作用。</span></span><span style=";font-family:Calibri;line-height:150%;font-size:19px">2014-004388-20)<span style="font-family:宋体">。</span><span style="font-family:Calibri">PI3Kδ</span><span style="font-family:宋体">抑制降低了肿瘤浸润性调节性</span><span style="font-family:Calibri">T (Treg)</span><span style="font-family:宋体">细胞的数量，增强了肿瘤浸润性</span><span style="font-family:Calibri">T</span><span style="font-family:宋体">细胞的细胞毒性潜能。在试验剂量的</span><span style="font-family:Calibri">AMG319</span><span style="font-family:宋体">中，</span><span style="font-family:Calibri">21</span><span style="font-family:宋体">例</span><span style="font-family:Calibri">AMG319</span><span style="font-family:宋体">患者中有</span><span style="font-family:Calibri">12</span><span style="font-family:宋体">例发生了</span></span><span style=";font-family:Calibri;line-height:150%;font-size:19px"><span style="font-family:宋体">免疫相关不良事件</span></span><span style=";font-family:Calibri;line-height:150%;font-size:19px">(irAEs)<span style="font-family:宋体">，需要停止治疗，这提示</span><span style="font-family:Calibri">AMG319</span><span style="font-family:宋体">对</span><span style="font-family:Calibri">Treg</span><span style="font-family:宋体">细胞有系统性影响。</span></span><span style=";font-family:Calibri;line-height:150%;font-size:19px"><span style="font-family:宋体">在小鼠模型中，</span>PI3Kδi<span style="font-family:宋体">系统地降低</span><span style="font-family:Calibri">Treg</span><span style="font-family:宋体">细胞数量，引起结肠炎。</span></span><span style=";font-family:Calibri;line-height:150%;font-size:19px"><span style="font-family:宋体">单细胞</span></span><span style=";font-family:宋体;line-height:150%;font-size:19px"><span style="font-family:Calibri">RNA</span></span><span style=";font-family:Calibri;line-height:150%;font-size:19px"><span style="font-family:宋体">测序分析显示，</span>pi3k δi<span style="font-family:宋体">驱动的结肠</span></span><span style=";font-family:Calibri;line-height:150%;font-size:19px"><span style="font-family:宋体">组织</span></span><span style=";font-family:Calibri;line-height:150%;font-size:19px">ST2 Treg<span style="font-family:宋体">细胞的缺失，伴随着致病性</span><span style="font-family:Calibri">T</span><span style="font-family:宋体">辅助细胞</span><span style="font-family:Calibri">17 (TH17)</span><span style="font-family:宋体">和</span><span style="font-family:Calibri">17</span><span style="font-family:宋体">型</span><span style="font-family:Calibri">CD8+ T (TC17)</span><span style="font-family:宋体">细胞的扩增，这可能是毒性的原因</span></span><span style=";font-family:宋体;line-height:150%;font-size:19px">。</span><span style=";font-family:宋体;line-height:150%;font-size:19px">通过间歇性给药的改进方法，发现能导致</span><span style=";font-family:Calibri;line-height:150%;font-size:19px"><span style="font-family:宋体">致肿瘤生长显著下降，而不诱导结肠组织中的致病性</span>T<span style="font-family:宋体">细胞，这表明替代给药方案可能限制毒性。</span></span></p><p style="line-height: 150%; text-indent: 2em;"><span style=";font-family:宋体;line-height:150%;font-size:19px"> </span></p><p style="line-height: 150%; text-indent: 2em;"><span style=";font-family:Calibri;line-height:150%;font-size:19px">PI3K<span style="font-family:宋体">抑制剂最初被认为主要针对癌细胞固有的</span><span style="font-family:Calibri">PI3K</span><span style="font-family:宋体">活性，这是在</span><span style="font-family:Calibri">B</span><span style="font-family:宋体">细胞恶性肿瘤中测试针对白细胞富集的</span><span style="font-family:Calibri">PI3Kδ</span><span style="font-family:宋体">抑制剂的基本原理。然而，随后的研究表明，</span><span style="font-family:Calibri">PI3Kδ</span><span style="font-family:宋体">抑制也有明显的免疫调节活性，主要是</span><span style="font-family:Calibri">T</span><span style="font-family:宋体">细胞介导的，这在</span><span style="font-family:Calibri">B</span><span style="font-family:宋体">细胞恶性肿瘤的早期试验中没有得到充分的重视，导致了</span><span style="font-family:Calibri">irae</span><span style="font-family:宋体">，阻碍了临床进展和效用。一些证据表明，</span><span style="font-family:Calibri">PI3Kδi</span><span style="font-family:宋体">优先抑制</span><span style="font-family:Calibri">Treg</span><span style="font-family:宋体">细胞，而不是其他</span><span style="font-family:Calibri">T</span><span style="font-family:宋体">细胞亚群</span><span style="font-family:Calibri">s4</span><span style="font-family:宋体">、</span><span style="font-family:Calibri">5</span><span style="font-family:宋体">、</span><span style="font-family:Calibri">6</span><span style="font-family:宋体">、</span><span style="font-family:Calibri">7</span><span style="font-family:宋体">、</span><span style="font-family:Calibri">8</span><span style="font-family:宋体">，但到目前为止，还没有在人类中进行过明确探索这一概念的试验。在这里，我们深入研究了</span><span style="font-family:Calibri">PI3Kδ</span><span style="font-family:宋体">抑制对实体肿瘤患者免疫细胞的影响，并探讨了导致</span><span style="font-family:Calibri">irae</span><span style="font-family:宋体">的机制。</span></span></p><p style="line-height: 150%; text-indent: 2em;"><span style=";font-family:宋体;line-height:150%;font-size:19px"> </span></p><p style="line-height: 150%; text-indent: 2em;"><span style=";font-family:Calibri;line-height:150%;font-size:19px">PI3Kδ<span style="font-family:宋体">抑制</span></span><span style=";font-family:宋体;line-height:150%;font-size:19px">可</span><span style=";font-family:Calibri;line-height:150%;font-size:19px"><span style="font-family:宋体">引起</span>irAEs</span></p><p style="line-height: 150%; text-indent: 2em;"><span style=";font-family:Calibri;line-height:150%;font-size:19px"><span style="font-family:宋体">为了评估</span>PI3Kδi<span style="font-family:宋体">作为人体实体癌免疫治疗药物的潜力，我们在一项新辅助、双盲、安慰剂对照的随机</span><span style="font-family:Calibri">II</span><span style="font-family:宋体">期试验中，将</span><span style="font-family:Calibri">PI3Kδi AMG319</span><span style="font-family:宋体">应用于未接受治疗的可切除头颈部鳞癌</span><span style="font-family:Calibri">(HNSCC)</span><span style="font-family:宋体">患者</span><span style="font-family:Calibri">(</span><span style="font-family:宋体">扩展数据图</span><span style="font-family:Calibri">1a</span><span style="font-family:宋体">，</span><span style="font-family:Calibri">b)</span><span style="font-family:宋体">。我们测量靶抑制</span><span style="font-family:Calibri">(</span><span style="font-family:宋体">使用磷酸化</span><span style="font-family:Calibri">AKT (pAKT)</span><span style="font-family:宋体">水平在</span><span style="font-family:Calibri">b</span><span style="font-family:宋体">细胞</span><span style="font-family:Calibri">)(</span><span style="font-family:宋体">扩展数据图</span><span style="font-family:Calibri">1c)</span><span style="font-family:宋体">和药物水平</span><span style="font-family:Calibri">(</span><span style="font-family:宋体">扩展数据图</span><span style="font-family:Calibri">1d)</span><span style="font-family:宋体">，以验证给药。</span><span style="font-family:Calibri">33</span><span style="font-family:宋体">名患者按</span><span style="font-family:Calibri">2:1</span><span style="font-family:宋体">的比例随机分配</span><span style="font-family:Calibri">(AMG319:</span><span style="font-family:宋体">安慰剂</span><span style="font-family:Calibri">)</span><span style="font-family:宋体">参加试验，</span><span style="font-family:Calibri">30</span><span style="font-family:宋体">名患者接受至少一剂</span><span style="font-family:Calibri">AMG319</span><span style="font-family:宋体">或安慰剂。</span><span style="font-family:Calibri">15</span><span style="font-family:宋体">名患者每天服用</span><span style="font-family:Calibri">400</span><span style="font-family:宋体">毫克</span><span style="font-family:Calibri">AMG319(</span><span style="font-family:宋体">每个患者</span><span style="font-family:Calibri">7-24</span><span style="font-family:宋体">天</span><span style="font-family:Calibri">)</span><span style="font-family:宋体">。</span></span><span style=";font-family:Calibri;line-height:150%;font-size:19px"><span style="font-family:宋体">出乎意料的是，在</span>400 mg<span style="font-family:宋体">的剂量下，</span><span style="font-family:Calibri">15</span><span style="font-family:宋体">名患者中有</span><span style="font-family:Calibri">9</span><span style="font-family:宋体">人出现了导致停药的</span></span><span style=";font-family:Calibri;line-height:150%;font-size:19px">irAEs</span><span style=";font-family:Calibri;line-height:150%;font-size:19px"><span style="font-family:宋体">。</span></span><span style=";font-family:Calibri;line-height:150%;font-size:19px"><span style="font-family:宋体">在正式的安全性审查之后，又招募了</span>6<span style="font-family:宋体">名患者，每天减少</span><span style="font-family:Calibri">300</span><span style="font-family:宋体">毫克的剂量进行治疗。同样，</span><span style="font-family:Calibri">6</span><span style="font-family:宋体">名患者中有</span><span style="font-family:Calibri">3</span><span style="font-family:宋体">名患有</span></span><span style=";font-family:Calibri;line-height:150%;font-size:19px">irAEs</span><span style=";font-family:Calibri;line-height:150%;font-size:19px"><span style="font-family:宋体">，导致停止治疗。</span>1<span style="font-family:宋体">例患者在完成</span><span style="font-family:Calibri">24</span><span style="font-family:宋体">次每日剂量的</span><span style="font-family:Calibri">AMG319</span><span style="font-family:宋体">后发生</span><span style="font-family:Calibri">4</span><span style="font-family:宋体">级结肠炎，最终需要结肠切除术</span><span style="font-family:Calibri">(</span><span style="font-family:宋体">图</span><span style="font-family:Calibri">1a)</span><span style="font-family:宋体">。最常见的</span><span style="font-family:Calibri">irae</span><span style="font-family:宋体">为皮疹</span><span style="font-family:Calibri">(29%;</span><span style="font-family:宋体">治疗组</span><span style="font-family:Calibri">25%</span><span style="font-family:宋体">，安慰剂组</span><span style="font-family:Calibri">4%)</span><span style="font-family:宋体">、腹泻</span><span style="font-family:Calibri">(29%;</span><span style="font-family:宋体">治疗组为</span><span style="font-family:Calibri">28%</span><span style="font-family:宋体">，安慰剂组为</span><span style="font-family:Calibri">1%)</span><span style="font-family:宋体">和转氨炎</span><span style="font-family:Calibri">(</span><span style="font-family:宋体">治疗组均为</span><span style="font-family:Calibri">14%)</span><span style="font-family:宋体">，与治疗介导的</span><span style="font-family:Calibri">Treg</span><span style="font-family:宋体">细胞或多种组织中</span><span style="font-family:Calibri">Treg</span><span style="font-family:宋体">细胞功能缺失引起的免疫病理一致。</span><span style="font-family:Calibri">irae</span><span style="font-family:宋体">的发病速度惊人地快</span><span style="font-family:Calibri">(</span><span style="font-family:宋体">到发病的中位时间为</span><span style="font-family:Calibri">9</span><span style="font-family:宋体">天</span><span style="font-family:Calibri">)</span><span style="font-family:宋体">，</span><span style="font-family:Calibri">21</span><span style="font-family:宋体">例</span><span style="font-family:Calibri">amg319</span><span style="font-family:宋体">治疗患者中有</span><span style="font-family:Calibri">12</span><span style="font-family:宋体">例停用治疗。在临床上，最可能反映了短暂的治疗期，我们在可评估的</span><span style="font-family:Calibri">23</span><span style="font-family:宋体">名患者的研究组之间没有观察到任何测量的肿瘤体积的显著差异。</span><span style="font-family:Calibri">amg319</span><span style="font-family:宋体">治疗的患者中有</span><span style="font-family:Calibri">2</span><span style="font-family:宋体">例出现部分缓解，</span><span style="font-family:Calibri">1</span><span style="font-family:宋体">例出现完全病理缓解</span><span style="font-family:Calibri">(</span><span style="font-family:宋体">扩展数据图</span><span style="font-family:Calibri">1c)</span><span style="font-family:宋体">，均为</span><span style="font-family:Calibri">3/4</span><span style="font-family:宋体">级</span></span><span style=";font-family:Calibri;line-height:150%;font-size:19px">irAEs</span><span style=";font-family:Calibri;line-height:150%;font-size:19px"><span style="font-family:宋体">。</span></span></p><p style="line-height: 150%; text-indent: 2em;"><span style=";font-family:Calibri;line-height:150%;font-size:19px"> <img src="https://cors.zfour.workers.dev/?http://image.sciencenet.cn/home/202205/07/100928qis3l51gq5305fts.png" title alt="图片1.png" referrerpolicy="no-referrer"></span></p><p style="line-height: 150%; text-indent: 2em;"><span style=";font-family:Calibri;line-height:150%;font-size:19px"><span style="font-family:宋体">图</span>1:PI3Kδi<span style="font-family:宋体">驱动抗肿瘤免疫，但引起显著的</span></span><span style=";font-family:Calibri;line-height:150%;font-size:19px">irAEs</span><span style=";font-family:Calibri;line-height:150%;font-size:19px"><span style="font-family:宋体">。</span></span></p><p style="line-height: 150%; text-indent: 2em;"><span style=";font-family:Calibri;line-height:150%;font-size:19px">PI3Kδi<span style="font-family:宋体">改变肿瘤微环境</span></span></p><p style="line-height: 150%; text-indent: 2em;"><span style=";font-family:Calibri;line-height:150%;font-size:19px"><span style="font-family:宋体">对治疗前和治疗后的肿瘤样本进行的全肿瘤</span></span><span style=";font-family:宋体;line-height:150%;font-size:19px"><span style="font-family:Calibri">RNA</span></span><span style=";font-family:Calibri;line-height:150%;font-size:19px"><span style="font-family:宋体">测序</span>(RNA-seq)<span style="font-family:宋体">分析显示，</span><span style="font-family:Calibri">AMG319</span><span style="font-family:宋体">治疗组存在显著差异</span><span style="font-family:Calibri">(93</span><span style="font-family:宋体">个差异表达基因</span><span style="font-family:Calibri">(DEGs))</span><span style="font-family:宋体">，但安慰剂组没有差异</span><span style="font-family:Calibri">(3</span><span style="font-family:宋体">个</span><span style="font-family:Calibri">DEGs)(</span><span style="font-family:宋体">图</span><span style="font-family:Calibri">1b)</span><span style="font-family:宋体">。作为</span><span style="font-family:Calibri">PI3Kδ</span><span style="font-family:宋体">抑制导致</span><span style="font-family:Calibri">FOXP3</span><span style="font-family:宋体">转录水平显著降低</span><span style="font-family:Calibri">(</span><span style="font-family:宋体">图</span><span style="font-family:Calibri">1 b)</span><span style="font-family:宋体">的肿瘤样本中</span><span style="font-family:Calibri">,</span><span style="font-family:宋体">我们评估</span><span style="font-family:Calibri">Treg</span><span style="font-family:宋体">通过免疫组织化学方法在肿瘤组织细胞水平</span><span style="font-family:Calibri">,</span><span style="font-family:宋体">假设之间的持续时间停止治疗和肿瘤切除可能是一个关键因素影响</span><span style="font-family:Calibri">Treg</span><span style="font-family:宋体">细胞丰度</span><span style="font-family:Calibri">,</span><span style="font-family:宋体">由于化合物的半衰期相对较短。事实上，我们发现只有在治疗后可以直接评估其丰度的患者中，肿瘤内</span><span style="font-family:Calibri">Treg</span><span style="font-family:宋体">细胞显著减少</span><span style="font-family:Calibri">(PI3Kδi</span><span style="font-family:宋体">短间隔</span><span style="font-family:Calibri">)(</span><span style="font-family:宋体">图</span><span style="font-family:Calibri">1c)</span><span style="font-family:宋体">，这意味着一旦治疗停止，</span><span style="font-family:Calibri">Treg</span><span style="font-family:宋体">细胞水平很快恢复正常。</span></span></p><p style="line-height: 150%; text-indent: 2em;"><span style=";font-family:Calibri;line-height:150%;font-size:19px"><span style="font-family:宋体">经过筛选的浸润肿瘤的</span>CD8+ T<span style="font-family:宋体">细胞的批量</span></span><span style=";font-family:宋体;line-height:150%;font-size:19px"><span style="font-family:Calibri">RNA</span></span><span style=";font-family:Calibri;line-height:150%;font-size:19px"><span style="font-family:宋体">测序分析显示，在处理后的样本中</span>IFNG<span style="font-family:宋体">、</span><span style="font-family:Calibri">GZMB</span><span style="font-family:宋体">和</span><span style="font-family:Calibri">PRF1</span><span style="font-family:宋体">的表达更高，表明</span><span style="font-family:Calibri">PI3Kδi</span><span style="font-family:宋体">处理增强了浸润肿瘤的</span><span style="font-family:Calibri">CD8+ T</span><span style="font-family:宋体">细胞的细胞毒性潜能</span><span style="font-family:Calibri">(</span><span style="font-family:宋体">图</span><span style="font-family:Calibri">1d)</span><span style="font-family:宋体">。</span></span><span style=";font-family:Calibri;line-height:150%;font-size:19px"><span style="font-family:宋体">我们通过单细胞</span>RNA-seq (scRNA-seq)<span style="font-family:宋体">分析证实了这些结果，结果表明</span><span style="font-family:Calibri">CD4+</span><span style="font-family:宋体">和</span><span style="font-family:Calibri">CD8+ T</span><span style="font-family:宋体">细胞簇表现出与治疗相关的细胞毒性基因表达增加</span><span style="font-family:Calibri">(</span><span style="font-family:宋体">例如，</span><span style="font-family:Calibri">GZMB</span><span style="font-family:宋体">和</span><span style="font-family:Calibri">PRF1)(</span><span style="font-family:宋体">扩展数据图</span><span style="font-family:Calibri">2a</span><span style="font-family:宋体">，</span></span><span style=";font-family:Calibri;line-height:150%;font-size:19px">b)<span style="font-family:宋体">。我们还发现治疗后</span><span style="font-family:Calibri">CD4+</span><span style="font-family:宋体">和</span><span style="font-family:Calibri">CD8+ T</span><span style="font-family:宋体">细胞有适度的克隆扩增</span><span style="font-family:Calibri">(</span><span style="font-family:宋体">扩展数据图</span><span style="font-family:Calibri">2c)</span><span style="font-family:宋体">。由于</span><span style="font-family:Calibri">CD4+FOXP3+ T</span><span style="font-family:宋体">细胞数量较低</span><span style="font-family:Calibri">(</span><span style="font-family:宋体">每个患者</span><span style="font-family:Calibri">0-27</span><span style="font-family:宋体">个</span><span style="font-family:Calibri">)</span><span style="font-family:宋体">，排除了我们队列中更详细的分析，我们下一步评估了循环</span><span style="font-family:Calibri">Treg</span><span style="font-family:宋体">细胞。</span><span style="font-family:Calibri">PI3Kδ</span><span style="font-family:宋体">抑制导致活化的循环</span><span style="font-family:Calibri">Treg</span><span style="font-family:宋体">细胞显著增加，而安慰剂组</span><span style="font-family:Calibri">Treg</span><span style="font-family:宋体">细胞的比例和激活状态保持稳定</span><span style="font-family:Calibri">(</span><span style="font-family:宋体">扩展数据图</span><span style="font-family:Calibri">2d, e)</span><span style="font-family:宋体">。这意味着，</span><span style="font-family:Calibri">PI3Kδ</span><span style="font-family:宋体">抑制要么影响增殖，要么取代组织中活化的</span><span style="font-family:Calibri">Treg</span><span style="font-family:宋体">细胞，可能是通过改变组织归巢因子的表达，如</span><span style="font-family:Calibri">KLF2</span><span style="font-family:宋体">和</span><span style="font-family:Calibri">S1PR1 (FOXO1</span><span style="font-family:宋体">的直接靶点，与之前的研究一致</span><span style="font-family:Calibri">5,6,7)</span><span style="font-family:宋体">，可能导致毒性。总之，这些数据表明，</span><span style="font-family:Calibri">PI3Kδ</span><span style="font-family:宋体">抑制引起肿瘤微环境</span><span style="font-family:Calibri">(TME)</span><span style="font-family:宋体">的深刻变化，其特征是</span><span style="font-family:Calibri">CD4+</span><span style="font-family:宋体">和</span><span style="font-family:Calibri">CD8+ T</span><span style="font-family:宋体">细胞活化增强，少克隆</span><span style="font-family:Calibri">T</span><span style="font-family:宋体">细胞扩增和细胞溶解活性增加，与肿瘤内</span><span style="font-family:Calibri">Treg</span><span style="font-family:宋体">细胞的减少一致。使</span><span style="font-family:Calibri">T</span><span style="font-family:宋体">细胞激活，并导致剂量限制毒性的快速开始。</span></span></p><p style="margin-left: 0px; text-indent: 28px; line-height: 150%;"><br></p>                    <br><br>
                                        <label style="font-size:13px; color:#850f0f">转载本文请联系原作者获取授权，同时请注明本文来自孙学军科学网博客。<br>链接地址：</label><a href="https://blog.sciencenet.cn/blog-41174-1337413.html" target="_blank" style="font-size:13px; color:#850f0f">https://blog.sciencenet.cn/blog-41174-1337413.html </a>
  <br><br>上一篇：<a href="http://blog.sciencenet.cn/blog-41174-1337266.html" target="_black">细菌合作还是竞争？这是个问题</a><br>                    <!--大赛结束-->
                                        
  
</div>
            